Evaluation of antidiabetic activity of Rajata bhasma

Abstract

Rajata bhasma (RB) has been used in the treatment of diabetes mellitus with its excellence for centuries, but their scientific evaluation has not thoroughly constituted with modern tools. The aim of the study was to evaluate the antidiabetic effect of RB in streptozotocin-induced diabetic rats. The different formulations RB1 (9 putas) and RB2 (17 putas) were prepared by the following classical methods. After the treatment with RB1 and RB2 to streptozotocin-treated rats, it significantly lowered the blood glucose level. Further, it also significantly decreased the elevated total cholesterol, triglycerides, and low-density lipoprotein level while increased the high-density lipoprotein. Glibenclamide was used as a standard drug at a dose of 0.50 mg/kg body weight. The present study shows that RB does have antidiabetic activity.